

REMARKS

Claims 1-9 are pending. Claims 8-9 are withdrawn from consideration as being directed to a non-elected invention. Claims 1-7 are being examined and are rejected.

Claims 1-7 are amended editorially to recite a "compound" instead of a "pyrrolopyrimidine derivative" or "pyrrolotriazine derivative." Claims 1-7 are also amended to delete various members of Markush groups.

Claim 8 is amended to recite a method of antagonizing CRF receptors, as supported, for example, in the Test Example at page 23. Claim 9 is amended to recite a method of treatment as supported, for example, at page 2, lines 12-19.

Accordingly, no new matter is added.

A. Restriction Requirement

The Examiner is requested, respectfully, to rejoin method claims 7 and 8, once claim 1 is found allowable.

B. Claim Objections

Claim 1 is objected to because it contains parentheses. The Examiner requires them to be deleted.

The parentheses have been removed from claim 1.

C. Claim Rejections - 35 USC § 112, 1st paragraph

Claims 1-7 are rejected under 35 U.S.C. 112, first paragraph, as lacking enablement. However, the Examiner states that the specification is enabling for a pyrrolopyrimidine or

pyrrolotriazine compound or pharmaceutically acceptable salt of Formula [I] wherein R^2 is alkyl; R^3 is hydrogen; and Ar is a substituted phenyl ring.

Without acquiescing in the merits of the rejection and in order to streamline prosecution, claims 1-7 have been amended to define the subject matter that the Examiner admits is enabled. Accordingly, the Examiner is requested, respectfully, to remove this rejection.

D. Claim Rejections - 35 USC § 112, 2nd paragraph

The Examiner rejects claims 1-7 under 35 U.S.C. 112, second paragraph, as being indefinite for reciting the phrases "pyrrolopyrimidine derivative" or "pyrrolotriazine derivative." The Examiner recommends replacing the terms "pyrrolopyrimidine derivative" or "pyrrolotriazine derivative" with the term "compound."

Without acquiescing in the rejection and solely to streamline prosecution, the claims have been amended to refer to "compounds." Accordingly, the Examiner is requested, respectfully, to remove the rejection.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT UNDER 37 C.F.R. § 1.111
Appln. No.: 10/584,946

Attorney Docket No.: Q95800

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: August 5, 2011

/Susan J. Mack/

Susan J. Mack

Registration No. 30,951